Journal article · 2026

Regulatory lessons from FDA review of approved AAV gene therapies

Sojin Bing, Takele Argaw, Megha Kaushal, Ronit Mazor

Nature Reviews Drug Discovery · Published 6 November 2026 · DOI 10.1038/d41573-026-00178-3

View at the publisherCite this paper

In brief

“Regulatory lessons from FDA review of approved AAV gene therapies” is a 2026 journal article by Sojin Bing and 3 co-authors, published in Nature Reviews Drug Discovery. OpenAlex counts 0 citations as of 16 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
0
Authors
4

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bing, S., Argaw, T., Kaushal, M., & Mazor, R. (2026). Regulatory lessons from FDA review of approved AAV gene therapies. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-026-00178-3

MLA 9

Bing, Sojin, et al. “Regulatory lessons from FDA review of approved AAV gene therapies.” Nature Reviews Drug Discovery, 2026. https://doi.org/10.1038/d41573-026-00178-3.

Chicago

Bing, Sojin, Takele Argaw, Megha Kaushal, and Ronit Mazor. 2026. “Regulatory lessons from FDA review of approved AAV gene therapies.” Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-026-00178-3.

Harvard

Bing, S. et al. (2026) ‘Regulatory lessons from FDA review of approved AAV gene therapies’, Nature Reviews Drug Discovery. doi:10.1038/d41573-026-00178-3.

IEEE

S. Bing, T. Argaw, M. Kaushal, and R. Mazor, “Regulatory lessons from FDA review of approved AAV gene therapies,” Nature Reviews Drug Discovery, 2026, doi: 10.1038/d41573-026-00178-3.

BibTeX

@article{bing2026regulatory,
  title     = {{Regulatory lessons from FDA review of approved AAV gene therapies}},
  author    = {Bing, Sojin and Argaw, Takele and Kaushal, Megha and Mazor, Ronit},
  journal   = {Nature Reviews Drug Discovery},
  year      = {2026},
  doi       = {10.1038/d41573-026-00178-3},
  url       = {https://doi.org/10.1038/d41573-026-00178-3}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research

  • adeno-associated virus
  • gene therapy
  • FDA regulatory review
  • regulatory approval
  • drug regulation
  • clinical trial oversight

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Bing, S., Argaw, T., Kaushal, M., & Mazor, R. (2026). Regulatory lessons from FDA review of approved AAV gene therapies. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-026-00178-3

How many times has this paper been cited?

0 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Sojin Bing, Takele Argaw, Megha Kaushal, Ronit Mazor.

What is the DOI of this paper?

10.1038/d41573-026-00178-3, permanently at https://doi.org/10.1038/d41573-026-00178-3. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.